BioSpace News Archive

Sexual harassment has been a big focus in the news as of late, but much of this focus has been primarily concerned with the harassment issues in Hollywood and the political sphere. However, the scientific community has long been criticized for being a hostile environment for women as well.

Genentech snagged a new regulatory approval for its hemophilia treatment, Hemlibra. On Thursday the U.S. Food and Drug Administration approved the medication for hemophilia A patients who do not have factor VIII inhibitors.

Company’s robotic technology offers access to Scarfree™ advanced endoscopy procedures.

Axcelead Drug Discovery Partners, Inc. announced today a non-exclusive license agreement to provide Axcelead with worldwide access to ERS Genomics’ CRISPR/Cas9 genome editing intellectual property to enhance their drug discovery service offering. ERS Genomics holds rights to the foundational CRISPR/Cas9 patent portfolio from Dr. Emmanuelle Charpentier, co-inventor of the breakthrough gene editing technology.

Presentation of full TG01 phase I/II clinical trial results in resected pancreatic cancer, by Professor Daniel Palmer

-Due to large backlog of applications, the Notified Body, LNE/G-MED, now expects completion of the process around year’s end

Soligenix, Inc. announced today that it has been invited to present results from two of its development programs at National Organization for Rare Disorders’ (NORD’s) Rare Diseases and Orphan Products Breakthrough Summit on October 15-16, 2018 in Washington, DC.

Firm Announces Launch of Blackstone Life Sciences Investment Platform

Baloxavir marboxil - a first-in-class, single-dose, investigational oral medicine - is the first potential influenza treatment in clinical trials to demonstrate a clinically meaningful benefit for people highly vulnerable to serious influenza complications

Phase 1 clinical program for PXL770 was observed to have a favorable pharmacokinetic, tolerability and safety profile